LeaderMed Group

What LeaderMed Group does

LeaderMed Group is a private, venture capital-backed pharmaceutical development company founded in 2020 and headquartered in New York, with Asian headquarters in Singapore and operational bases in Princeton (NJ), Shanghai, and Nantong (China). The company runs an end-to-end drug development platform spanning IP creation, clinical efficacy testing, regulatory approval, manufacturing, marketing, sales, and distribution, with a strategic emphasis on bringing innovative drugs to market faster in Asia-Pacific than in the US and Europe. Its core proprietary pipeline includes LM008, a first-in-class long-acting dual GLP-1R and glucagon receptor agonist targeting diabetes, obesity, diabetic kidney disease, and NASH (planned Phase III initiation by end of 1Q 2023, China approval targeted 2026), and LM007, a third-generation long-acting FVIIa therapy for hemophilia A and B. The company has also licensed the ALT-100 eNAMPT-neutralizing mAb platform from Aqualung Therapeutics for Asia-Pacific development in inflammatory disorders.

Name

LeaderMed Group

Legal name

LeaderMed Health Group Limited

Website

https://leadermedgroup.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

LeaderMed Group is a private Asia-Pacific-focused pharmaceutical development company developing first-in-class therapeutics for diabetes, obesity, hemophilia, and inflammatory disorders, and offering CRO/CDMO services across China, EMEA, and FDA territories.

Ownership category

akta.pro rank

Product category

Pharmaceutical Development Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical development
• Drug pipeline
• Clinical research services
• Contract manufacturing
• Asia-Pacific licensing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Development Services: CRO and CDMO services for drug development in China, Europe, Middle East, Africa, and FDA territories
2. Drug Pipeline Commercialization: In-licensing and acquisitions of pharmaceutical products for Asia-Pacific marketing and distribution
3. Asia-Pacific Regional Licensing: Revenue from licensing Asia-Pacific rights for drug development, manufacturing, and commercialization of partnered products

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

LeaderMed Group is an Asia-Pacific-focused pharmaceutical development company operating an integrated platform spanning IP creation, clinical efficacy testing, regulatory approval, manufacturing, marketing, sales and distribution. Its core offering includes proprietary drug candidates (LM008 dual GLP-1R/glucagon receptor agonist for diabetes and obesity; LM007 long-acting FVIIa for hemophilia) plus CRO/CDMO services and Asia-Pacific licensing for partnered products.

Product overview

LeaderMed Group is an ideation-to-IND to NDA pharmaceutical development company with Asia-Pacific manufacturing, marketing, and distribution capabilities. The company operates a global pharmaceutical platform encompassing IP creation, clinical efficacy testing, regulatory approval, manufacturing, marketing, sales, and distribution. Its core product pipeline includes LM008, a first-in-class long-acting dual GLP-1R and Glucagon receptor agonist for diabetes, obesity, and diabetic kidney disease, and LM007, a third-generation long-acting FVIIa drug for treating hemophilia A and B. The company also provides CRO and CDMO services and has licensed the ALT-100 platform (eNAMPT-neutralizing monoclonal antibody) from Aqualung Therapeutics for anti-inflammatory therapeutic applications.

Differentiator

Problem solved

Functional benefit

Brands

• LeaderMed Health Group Limited: Formal legal entity name for LeaderMed Group's operations

Products and services

• LM008

Quantifiable outcome

• Regulatory approval timeline faster in Asia-Pacific compared to US/Europe markets
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Aqualung TherapeuticscoreStrategic or Co-development Partner · 26 April 2022License agreement providing LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the eNAMPT-neutralizing mAb, ALT-100 platform technology. Based on strong preclinical results, LeaderMed and Aqualung will collaborate on Multi-Regional Clinical Trials (MRCT) designs for multiple indications including ARDS. Terms involve customary upfront fees, achievement milestones, and royalties coinciding with commercial sales. Aqualung is an early-stage biotech developing immune-focused therapeutic antibodies for disorders characterized by acute and chronic lung and systemic inflammation.
• OPKO HealthcoreStrategic or Co-development Partner · 14 September 2021LeaderMed Health Group Limited and OPKO Health, Inc. (NASDAQ: OPK) formed a joint venture to develop, manufacture and commercialize two of OPKO's clinical stage, long-acting drug products in Greater China and eight other Asian territories. OPKO is a diversified healthcare company focused on diagnostics and pharmaceuticals with first-in-class products including Rayaldee and 4Kscore test, robust R&D pipeline, and BioReference Laboratories and GeneDx diagnostics divisions. Dr. Phillip Frost is OPKO's founder and CEO.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Pharmaron: Global CRO/CDMO with major China operations covering preclinical through commercial manufacturing, comparable to LeaderMed's integrated CRO/CDMO model targeting Western biopharma clients seeking China entry.
• Asymchem Laboratories: China-based CDMO specializing in small-molecule API development and manufacturing with CMC documentation support — directly comparable to LeaderMed's CDMO/CMC service line, particularly for LM008/LM007.
• WuXi AppTec: Global CRO/CDMO with deep China operations offering integrated drug discovery, development and manufacturing services — the same end-to-end 'ideation to NDA' platform LeaderMed targets, but at vastly greater scale.
• Sciwind Biosciences: China-focused developer of long-acting GLP-1 and related metabolic biologics, the closest therapeutic-area peer competing with LM008 in the Chinese diabetes/obesity market.
• WuXi Biologics: Global biologics CDMO with end-to-end development and manufacturing capacity from China — overlapping LeaderMed's CRO/CDMO service offering, particularly for biologic modalities like LM007 (FVIIa) and ALT-100 (mAb).
• Tigermed: Leading China-based clinical CRO with multi-regional trial capabilities across Asia, closely overlapping LeaderMed's CRO footprint and hospital-recruitment advantage in China.

Broad incumbents

• Innovent Biologics: Established Chinese biopharma commercializing innovative biologics (including metabolic and oncology assets) with its own regulatory and commercial platform, a scaled comparator for LeaderMed's ambitions in China.
• BeiGene: Global, China-rooted oncology-focused biotech with established China commercial infrastructure and MRCT experience — illustrating the scaled version of LeaderMed's China-rooted, globally-sourced clinical pipeline model.
• Hansoh Pharmaceutical: Major China-listed innovative pharma with strong cardiometabolic and specialty franchise presence — a benchmark for the commercial scale and pipeline depth LeaderMed aspires to in China.

Emerging players

• Akeso: Chinese clinical-stage biotech developing novel biologics (including bispecifics) for metabolic and inflammatory diseases, with a comparable profile of clinical-stage first-in-class assets targeting Asia-Pacific markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/LeadermedGroup
• Facebookfacebook.com/leadermedwellness
• LinkedInlinkedin.com/company/leadermed-health-group-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LeaderMed Group